Summary
The elimination of the low molecular weight proteinase inhibitor camostate (FOY 305) was studied in rats after oral administration and in the the situ perfused rat liver. After feeding of camostate (400 mg/kg b. w.) only the metabolites (FOY 251, GBA) were detected in blood samples withdrawn from the portal and hepatic vein. This indicated a rapid degradation of FOY 305 after absorption from the gut lumen. The hepatic extraction of the anti-proteolytic active metabolite FOY 251 during a single liver passage was 23%. It remained almost constant over the period of 120 min.
In the perfused rat liver, FOY 305 was given in concentrations comparable to the in vivo studies. It was eliminated by 20%. In these experiments, the compound was metabolized to FOY 251 and in minor amounts to guanidino-benzoate (GBA), the latter being an anti-proteolytic ineffective degradation product.
In conclusion, a low hepatic extraction of FOY 305 led to pharmacologically effective concentrations of the active metabolite FOY 251 in the circulation after oral ingestion of the proteinase inhibitor.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Banauch D, Brümmer W, Ebeling W, Metz H, Rindfrey H, Leybold K, Rick W (1975) Eine Glucose-Dehydrogenase für die Glucose-Bestimmung in Körpersäften. Z Chem Klin Biochem 13:101–107
Fölsch UR, Cantor P, Wilms HM, Schafmayer A, Becker HD, Creutzfeldt W (1987) Role of cholecystokinin in the negative feedback control of pancreatic enzyme secretion in conscious rats. Gastroenterology 92:449–458
Göke B, Stöckmann F, Müller R, Lankisch PG, Creutzfeldt W (1984) Effect of a specific serine protease inhibitor on the rat pancreas: systemic administration of camostate and exocrine pancreatic secretion. Digestion 30:171–178
Göke B, Müller R, Lankisch PG (1984) Unpublished observation
Göke B, Printz H, Koop I, Rausch U, Richter G, Arnold R, Adler G (1986) Endogeneous CCK release and pancreatic growth in rats after feeding a proteinase inhibitor (camostate). Pancreas 1:509–515
Göke B, Adler G (1987) Biochemische Grundlagen der Wirkung von Aprotinin und der synthetischen Proteinasen-Inhibitoren Gabexat Mesilat und Camostate. Ergebnisse der Gastroenterologie 1986. Demeter, Gräfelfing, pp 148–150
Hartmann H, Beckh K, Jungermann K (1982) Direct control of glycogen metabolism in the perfused rat liver by the splanchnic innervation. Eur J Biochem 123:521–526
Liddle RA, Goldfine ID, Williams JA (1984) Bioassay of plasma cholecystokinin in rats: effects of food, trypsin inhibitors, and alcohol. Gastroenterology 87:542–549
Muramatu M, Shiraishi S, Fujii S (1972) Inhibitory effects of ε-amino and ε-guanidino acid esters on the first component of human complement. Biochim Biophys Acta 285:224–234
Noll F (1974) Lactat-Bestimmung mit LDH, GPT und NAD. In: Bergmeyer HU (ed) Methoden der enzymatischen Analyse. Verlag Chemie, Weinheim, pp 1521–1525
Saitoh Y (1982) Clinical results with an oral protease inhibitor FOY 305 in chronic pancreatitis. In: Grözinger KH, Schrey A, Wabnitz RW (eds) Proteinasen-Inhibition. Wolf, München, pp 156–167
Takasugi S, Yonezawa H, Ikei N, Kanno T (1982) Prevention of acute experimental pancreatitis in rats and dogs by intraduodenal infusion of a synthetic trypsin inhibitor. Digestion 24:36–41
Wernze H (1970) Einfache Technik zur Katheterisierung der V. hepatica bei der Ratte in situ. Z Ges Exp Med 153:234–236
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Beckh, K., Göke, B., Müller, R. et al. Elimination of the low-molecular weight proteinase inhibitor camostate (FOY 305) and its degradation products by the rat liver. Res. Exp. Med. 187, 401–406 (1987). https://doi.org/10.1007/BF01852177
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01852177